Mariette Boerstoel Streefland

Until the AZ acquisition of Alexion, Mariette was is SVP, Pharmacovigilance and Head of Global Safety at Alexion Pharmaceuticals, Inc, a world leader in rare diseases from 2018, hired to turn around the safety organization. Prior to her role at Alexion, Mariette was SVP, Head of Global Drug Safety at Shire, having been appointed to lead the safety organization after the Baxalta acquisition in 2016. She joined Baxalta two years prior to establish their safety department with the split off from Baxter. Mariette joined the pharmaceutical industry from clinical practice and had a progressive career for 30 years, holding various leadership positions in drug safety and medical affairs at Organon (now Merck), Mayne Pharma (now Hospira), Forest Labs (now Allergan). A common theme across the various roles has been organizational build or re-design, turn around management, change management, efficiency, and quality improvement initiatives.

Mariette received her MD degree from the University of Utrecht, her master’s degree in Pharmaco-Epidemiology from McGill University Montreal and the University of Utrecht, and her MBA from New York Institute of Technology/Ellis College.